Danaher Corporation $DHR Stock Position Boosted by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. raised its position in Danaher Corporation (NYSE:DHR) by 2,444,444.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 220,009 shares of the conglomerate’s stock after purchasing an additional 220,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.’s holdings in Danaher were worth $48,831,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of DHR. Danske Bank A S boosted its position in Danaher by 16.6% during the 3rd quarter. Danske Bank A S now owns 379,684 shares of the conglomerate’s stock worth $84,119,000 after acquiring an additional 54,035 shares during the last quarter. Cornerstone Advisory LLC grew its stake in shares of Danaher by 9.3% during the 3rd quarter. Cornerstone Advisory LLC now owns 1,960 shares of the conglomerate’s stock worth $434,000 after acquiring an additional 166 shares in the last quarter. Diversified Trust Co grew its stake in shares of Danaher by 26.5% during the 3rd quarter. Diversified Trust Co now owns 7,228 shares of the conglomerate’s stock worth $1,601,000 after acquiring an additional 1,514 shares in the last quarter. BCV Asset Management Inc. raised its holdings in shares of Danaher by 0.3% in the third quarter. BCV Asset Management Inc. now owns 322,294 shares of the conglomerate’s stock valued at $71,694,000 after purchasing an additional 1,028 shares during the last quarter. Finally, Valmark Advisers Inc. raised its holdings in shares of Danaher by 3.0% in the third quarter. Valmark Advisers Inc. now owns 1,800 shares of the conglomerate’s stock valued at $399,000 after purchasing an additional 53 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.4%

DHR stock traded up $1.00 during mid-day trading on Friday, reaching $233.16. The company had a trading volume of 3,359,470 shares, compared to its average volume of 4,152,061. The company has a market capitalization of $164.04 billion, a price-to-earnings ratio of 38.16, a PEG ratio of 2.92 and a beta of 0.76. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The stock has a 50 day simple moving average of $222.56 and a two-hundred day simple moving average of $201.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The company had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. During the same quarter in the prior year, the business posted $1.89 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. As a group, equities analysts predict that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were paid a $0.40 dividend. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is currently 26.19%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DHR. TD Cowen boosted their price objective on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. UBS Group restated a “buy” rating and set a $260.00 target price on shares of Danaher in a report on Thursday, October 22nd. DZ Bank downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Royal Bank Of Canada lifted their price target on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Finally, Guggenheim boosted their price target on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $242.91.

Insiders Place Their Bets

In related news, CAO Christopher Bouda sold 7,598 shares of the business’s stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the transaction, the chief accounting officer directly owned 9,107 shares in the company, valued at approximately $2,136,137.92. The trade was a 45.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregory Milosevich sold 2,100 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $230.62, for a total transaction of $484,302.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $5,158,277.54. This trade represents a 8.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 10.80% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.